Xeinadin Group, Ltd.

Canaccord Genuity Acts as Sole Financial Adviser to Xeinadin Group on a Significant Minority Investment from Exponent Private Equity

​​​​​​​Canaccord Genuity is pleased to announce that it has acted as sole financial adviser to Xeinadin Group Limited (“Xeinadin” or the “Group”) on a significant minority investment from Exponent Private Equity LLP (“Exponent”).

Canaccord Genuity advised on a sellside process which generated a high level of competitive interest from potential investors.

Xeinadin has more than 1,500 employees across the UK & Ireland and is one of the professional services market’s leading disruptors and consolidators. The Group provides over 40 business advisory and accountancy service lines to over 50,000 clients.

The investment by Exponent will support the Group’s ambitions to grow significantly, both organically and through acquisitions, and allow it to make further investments in innovative data-driven technologies to help drive efficiencies and improve the quality, breadth, and delivery of services to its clients.

Subject to regulatory approvals, the transaction is expected to complete in Q1 2022.